The Columbia community gathered in the Hudson Valley for the eighth annual Velocity: Columbia’s Ride to End Cancer. This year’s event raised more than $1 million and attracted nearly 600 participants.
Columbia researchers have engineered bacteria as personalized cancer vaccines that activate the immune system to specifically seek out and destroy cancer cells.
Physician-scientist Juanma Schvartzman is a firm believer that his curiosity-driven research on cell metabolism and its influence on cell identity will offer clues for better cancer treatments.
Velocity is a new cycling event that benefits the Herbert Irving Comprehensive Cancer Center at CUIMC. Columbia riders share why they joined the cause.
Researchers discovered a mechanism that reprograms tumor cells in patients with advanced prostate cancer, reducing their response to anti-androgen therapy.
Based on new evidence, laparoscopic surgery should be offered to most women with early-stage endometrial cancer, says Columbia’s gynecologic cancer chief.
The drug, developed by Columbia and MSK researchers, selectively kills cancer cells and has shown activity against multiple malignancies in pre-clinical studies.
Bristol-Myers Squibb Company today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre have joined the International Immuno-Oncology Network.
In her JAMA editorial, Columbia oncologist Dawn Hershman says clinical trials show cooling caps reduce hair loss in some women undergoing chemotherapy.
Collaboration will investigate a system biology approach to identifying treatment options for patients with advanced gastrointestinal stromal tumors (GIST).